The contribution of genetic factors to thrombotic and bleeding outcomes in coronary patients randomised to IIb/IIIa antagonists
- 1 March 2002
- journal article
- clinical trial
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 2 (3) , 182-190
- https://doi.org/10.1038/sj.tpj.6500100
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Association of IL-1beta and IL-1 receptor antagonist haplotypes with rate of decline in lung function in smokersThorax, 2001
- Genetic case-control association studies - correcting for multiple testingHuman Genetics, 2001
- Stromelysin-1 and Interleukin-6 Gene Promoter Polymorphisms Are Determinants of Asymptomatic Carotid Artery AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2000
- The Future of Antiplatelet Therapy: Optimizing Management in Patients with Acute Coronary SyndromeClinical Cardiology, 2000
- Interleukin-1 polymorphisms associated with increased risk of gastric cancerNature, 2000
- Polymorphisms in glycoprotein (GP) lb alpha are not associated with adverse outcomes in primigravidaeJournal of Obstetrics and Gynaecology, 2000
- Genotyping single nucleotide polymorphisms by primer extension and high performance liquid chromatographyHuman Genetics, 1999
- Association of two silent polymorphisms of platelet glycoprotein la/lla receptor with risk of myocardial infarction: a case-control studyThe Lancet, 1999
- The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis.Journal of Clinical Investigation, 1998
- Some Thoughts on Clinical Trials, Especially Problems of MultiplicityScience, 1977